Kinoshita et al., 2017 - Google Patents
In vivo lipopolysaccharide tolerance recruits CD11b+ macrophages to the liver with enhanced bactericidal activity and low tumor necrosis factor-releasing capability …Kinoshita et al., 2017
View PDF- Document ID
- 634103251374630633
- Author
- Kinoshita M
- Miyazaki H
- Nakashima H
- Nakashima M
- Nishikawa M
- Ishikiriyama T
- Kato S
- Iwaya K
- Hiroi S
- Shinomiya N
- Seki S
- Publication year
- Publication venue
- Journal of innate immunity
External Links
Snippet
Objectives: In vivo lipopolysaccharide (LPS) tolerance on bacterial infection was investigated, focusing on liver macrophages. Methods: LPS tolerance was induced by intraperitoneal injections with 5 μg/kg of LPS for 3 consecutive days, and then mice were …
- 239000002158 endotoxin 0 title abstract description 136
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kinoshita et al. | In vivo lipopolysaccharide tolerance recruits CD11b+ macrophages to the liver with enhanced bactericidal activity and low tumor necrosis factor-releasing capability, resulting in drastic resistance to lethal septicemia | |
| Matsushita et al. | BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance | |
| Zajd et al. | Bone marrow-derived and elicited peritoneal macrophages are not created equal: the questions asked dictate the cell type used | |
| Sato et al. | Involvement of the TNF and FasL produced by CD11b Kupffer cells/macrophages in CCl4-induced acute hepatic injury | |
| Murai et al. | Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction | |
| Lee et al. | Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection | |
| Smyth et al. | Differential tumor surveillance by natural killer (NK) and NKT cells | |
| Andzinski et al. | Type I IFN s induce anti‐tumor polarization of tumor associated neutrophils in mice and human | |
| Wysocki et al. | Critical role for CCR5 in the function of donor CD4+ CD25+ regulatory T cells during acute graft-versus-host disease | |
| Khan et al. | PD-L1hi B cells are critical regulators of humoral immunity | |
| Mun et al. | TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection | |
| Miyazaki et al. | IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection | |
| Lucas et al. | Dendritic cells prime natural killer cells by trans-presenting interleukin 15 | |
| Wang et al. | Interleukin-35 induces regulatory B cells that suppress autoimmune disease | |
| Maecker et al. | TWEAK attenuates the transition from innate to adaptive immunity | |
| Geherin et al. | The skin, a novel niche for recirculating B cells | |
| Almishri et al. | TNFα augments cytokine-induced NK cell IFNγ production through TNFR2 | |
| Delano et al. | MyD88-dependent expansion of an immature GR-1+ CD11b+ population induces T cell suppression and Th2 polarization in sepsis | |
| Schmid et al. | Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes | |
| Bugl et al. | Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling | |
| Robb et al. | Type I-IFNs control GVHD and GVL responses after transplantation | |
| Palmer et al. | Signaling thresholds govern heterogeneity in IL‐7‐receptor‐mediated responses of naïve CD8+ T cells | |
| Maeda et al. | Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease | |
| Bonaccorsi-Riani et al. | Iron deficiency impairs intra-hepatic lymphocyte mediated immune response | |
| Li et al. | Effect of IL-18 on Expansion of γδ T Cells Stimulated by Zoledronate and IL-2 |